Arrowhead buys PRV for $215M; Twist hopes to raise $300M in public offeringnews2026-08-05T14:28:57+00:00August 5th, 2026|Endpoints News|
Otsuka succeeds with kidney drug; BioNTech downgrades revenue projectionnews2026-08-04T14:50:59+00:00August 4th, 2026|Endpoints News|
Curium buys radiopharma rival Lantheus for $8B; Sandoz settles price-fixing casenews2026-08-03T14:28:13+00:00August 3rd, 2026|Endpoints News|
Ratio collects $70M for its radiopharmaceutical trials; Vogenx plans $67M IPOnews2026-07-31T14:59:38+00:00July 31st, 2026|Endpoints News|
Pfizer’s Phase 3 win for Litfulo; Braveheart, Attovia eye IPOs of $275M, $182Mnews2026-07-30T15:16:51+00:00July 30th, 2026|Endpoints News|
Atea’s hep C pill equal to Gilead’s; AbCellera inks second deal in two monthsnews2026-07-29T15:17:35+00:00July 29th, 2026|Endpoints News|
Oak Hill Bio merges with RA Capital SPAC; InnoCare’s TYK2 drug hits in Phase 3news2026-07-28T15:17:47+00:00July 28th, 2026|Endpoints News|
Yarrow to begin trading as it targets Graves; FDA approves Otsuka’s ADHD pillnews2026-07-27T15:40:29+00:00July 27th, 2026|Endpoints News|
Novo asks court to block Lilly ads; Merck strikes HIV PrEP dealnews2026-07-24T14:08:57+00:00July 24th, 2026|Endpoints News|
Scancell plans Neuphoria merger; AstraZeneca wins EU nod for cancer drugnews2026-07-23T14:47:25+00:00July 23rd, 2026|Endpoints News|
